Patients with various primary diseases and AA amyloidosis: demographic parameters at visit 1
| A: cid+AA | B: idio+AA | C: auto+AA | P value (AB vs C) | |
| Patients, n | 34 | 25 | 24 | ns |
| Female gender, n (%) | 26 (76.5) | 17 (68.0) | 11 (45.8) | 0.045 |
| Age at AA (years), mean (SEM) | 60.9 (1.9) | 63.1 (2.2) | 46.6 (2.0) | 0.0001 |
| Age at disease onset (years), mean (SEM) | 45.2 (3.0) | Unknown | 31.7 (3.5) | ns |
| Treatment V1 to last visit (years), mean (SEM) | 5.95 (1.07) | 4.54 (1.10) | 3.96 (0.81) | ns |
| Amyloid in renal biopsy, n (%) | 34 (100) | 25 (100) | 24 (100) | ns |
| Amyloid in FAB, n (%) | 22 (64.7) | 15 (60.0) | 8 (33.4) | 0.028 |
| GIT amyloidosis, n (%) | 14 (41.2) | 10 (40.0) | 11 (45.8) | ns |
| Heart amyloidosis, n (%) | 4 (11.8) | 1 (4.0) | 4 (16.7) | ns |
| Serum creatinine at V1 (mg/dL), n (%) | ||||
| <2.5 | 20 (58.8) | 14 (56.0) | 21 (87.5) | 0.010 |
| 2.5–5 | 10 (29.4) | 8 (32.0) | 3 (12.5) | ns |
| ESRD at V1, n (%) | 4 (11.8) | 3 (12.0) | 0 (0.0) | ns |
| Protein to creatinine ratio at V1 (g/mol), n (%) | ||||
| <300 | 13 (38.2) | 8 (32.0) | 11 (45.8) | ns |
| 300–1000 | 7 (20.6) | 8 (32.0) | 9 (37.5) | ns |
| >1000 | 14 (41.2) | 9 (36.0) | 4 (16.7) | ns |
| Primary disease, n | Arthritis: 18 IBD: 8 Others: 8 | Idiopathic: 25 | FMF: 22 CAPS: 2 | |
| Previous csDMARD, n (%) | 30 (96.8) | 0 | 23 (95.8) | 0.001 |
| Previous bDMARD, n (%) | 14 (45.1) | 0 | 22 (91.7) | 0.001 |
| BMI (kg/m2), mean (SEM) | 27.54 (4.59) | 32.38 (8.36) | 26.84 (5.86) | 0.0001 |
| SAA1α/α, n (%) | 21 (93.3) | 20 (100) | 9 (45.0) | 0.0000 |
AA, AA amyloidosis; auto+AA, patients with an autoinflammatory syndrome and AA amyloidosis; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; CAPS, cryopyrin-associated periodic syndrome; cid+AA, patients with chronic inflammatory diseases and AA amyloidosis; csDMARD, corticosteroid-sparing disease-modifying antirheumatic drug; ESRD, end-stage renal disease; FAB, fat tissue aspiration biopsy; FMF, familial Mediterranean fever; GIT, gastrointestinal tract; IBD, inflammatory bowel disease; idio+AA, patients with idiopathic AA amyloidosis; SAA, serum amyloid alpha; V1, visit 1.